Human Chorionic Villous Mesenchymal Stem Cells Modify the Functions of Human Dendritic Cells, and Induce an Anti-Inflammatory Phenotype in CD1+ Dendritic Cells

Stem Cell Reviews and Reports

Volumn 11, Issue 3, 2015, Pages 423-441

  Abomaray, F M ^a   Al Jumah, M A ^a   Kalionis, B ^b   AlAskar, A S ^a,c   Al Harthy, S ^d   Jawdat, D ^a,c   Al Khaldi, A ^c   Alkushi, A ^a   Knawy, B A ^a,c   Abumaree, M H ^a  

^a KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES   (Saudi Arabia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES   (Saudi Arabia)

^d KING ABDULAZIZ CITY FOR SCIENCE AND TECHNOLOGY   (Saudi Arabia)

Author keywords

Chorionic villi mesenchymal stem cells; Dendritic cells; Immune modulation; Inflammation cells; T cell proliferation

Indexed keywords

B7 ANTIGEN; CD40 ANTIGEN; CD83 ANTIGEN; CD86 ANTIGEN; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INDOLEAMINE 2, 3 DIOXYGENASE; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 23; INTERLEUKIN 4; INTERLEUKIN 6; LEUKEMIA INHIBITORY FACTOR; LIPOPOLYSACCHARIDE; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 2; PROSTAGLANDIN E2; T6 ANTIGEN; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; V SET DOMAIN CONTAINING T CELL ACTIVATION INHIBITOR 1; VASCULOTROPIN; CD1 ANTIGEN;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CELL PROLIFERATION; CELL PROLIFERATION ASSAY; CHORION VILLUS; COCULTURE; CONTROLLED STUDY; DENDRITIC CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MAJOR HISTOCOMPATIBILITY COMPLEX; MESENCHYMAL STEM CELL; MONOCYTE; NORMAL HUMAN; PHAGOCYTOSIS; PHENOTYPE; PLACENTA; PRIORITY JOURNAL; T LYMPHOCYTE; CELL DIFFERENTIATION; CYTOLOGY; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; MESENCHYMAL STROMA CELL; METABOLISM; PREGNANCY;

ANTIGENS, CD1; CELL DIFFERENTIATION; CELL PROLIFERATION; CHORIONIC VILLI; COCULTURE TECHNIQUES; DENDRITIC CELLS; FEMALE; GENE EXPRESSION REGULATION, DEVELOPMENTAL; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INTERLEUKIN-4; MESENCHYMAL STROMAL CELLS; MONOCYTES; PLACENTA; PREGNANCY;

EID: 84930639631     PISSN: 15508943     EISSN: 15586804     Source Type: Journal    
DOI: 10.1007/s12015-014-9562-8     Document Type: Article

References (82)

1. Augello, A., Kurth, T. B., & De Bari, C. (2010). Mesenchymal stem cells: a perspective from in vitro cultures to in vivo migration and niches. European Cells & Materials, 20, 121–133.
2. Krampera, M., Pizzolo, G., Aprili, G., & Franchini, M. (2006). Mesenchymal stem cells for bone, cartilage, tendon and skeletal muscle repair. Bone, 39, 678–683.
3. Phinney, D. G., & Prockop, D. J. (2007). Concise review: mesenchymal stem/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair–current views. Stem Cells, 25, 2896–2902.
4. Tanaka, M., & Miyajima, A. (2012). Identification and isolation of adult liver stem/progenitor cells. Methods in Molecular Biology, 826, 25–32.
5. Sakaguchi, Y., Sekiya, I., Yagishita, K., & Muneta, T. (2005). Comparison of human stem cells derived from various mesenchymal tissues: superiority of synovium as a cell source. Arthritis and Rheumatism, 52, 2521–2529.
6. Roubelakis, M. G., Pappa, K. I., Bitsika, V., et al. (2007). Molecular and proteomic characterization of human mesenchymal stem cells derived from amniotic fluid: comparison to bone marrow mesenchymal stem cells. Stem Cells and Development, 16, 931–952.
7. Anker PS, I. ’t., Scherjon, S. A., Kleijburg-vander Keur, C., et al. (2004). Isolation of mesenchymal stem cells of fetal or maternal origin from human placenta. Stem Cells, 22, 1338–1345.
8. Kanematsu, D., Shofuda, T., Yamamoto, A., et al. (2011). Isolation and cellular properties of mesenchymal cells derived from the decidua of human term placenta. Differentiation; Research in Biological Diversity, 82, 77–88.
9. Pelagiadis, I., Relakis, K., Kalmanti, L., & Dimitriou, H. (2012). CD133 immunomagnetic separation: effectiveness of the method for CD133(+) isolation from umbilical cord blood. Cytotherapy, 14, 701–706.
10. Gronthos, S., Arthur, A., Bartold, P. M., & Shi, S. (2011). A method to isolate and culture expand human dental pulp stem cells. Methods in Molecular Biology, 698, 107–121.
11. Abumaree, M.H., Al Jumah, M.A., Kalionis, B., et al. (2013). Phenotypic and functional characterization of mesenchymal stem cells from chorionic villi of human term placenta. Stem Cell Reviews, 9(1), 16–31. doi: 10.1007/s12015-012-9385-4.
12. Castrechini, N. M., Murthi, P., Gude, N. M., et al. (2010). Mesenchymal stem cells in human placental chorionic villi reside in a vascular Niche. Placenta, 31, 203–212.
13. Abumaree, M. H., Al Jumah, M. A., Kalionis, B., et al. (2013). Phenotypic and functional characterization of mesenchymal stem cells from chorionic villi of human term placenta. Stem Cell Reviews, 9, 16–31.
14. Al Jumah, M. A., & Abumaree, M. H. (2012). The immunomodulatory and neuroprotective effects of Mesenchymal Stem Cells (MSCs) in Experimental Autoimmune Encephalomyelitis (EAE): a model of Multiple Sclerosis (MS). International Journal of Molecular Sciences, 13, 9298–9331.
15. Abumaree, M. H., Al Jumah, M. A., Kalionis, B., et al. (2013). Human placental mesenchymal stem cells (pMSCs) play a role as immune suppressive cells by shifting macrophage differentiation from inflammatory M1 to anti-inflammatory M2 macrophages. Stem Cell Reviews, 9, 620–641.
16. Li, Y. P., Paczesny, S., Lauret, E., et al. (2008). Human mesenchymal stem cells license adult CD34+ hemopoietic progenitor cells to differentiate into regulatory dendritic cells through activation of the Notch pathway. Journal of Immunology, 180, 1598–1608.
17. Liu, W. H., Liu, J. J., Wu, J., et al. (2013). Novel mechanism of inhibition of dendritic cells maturation by mesenchymal stem cells via interleukin-10 and the JAK1/STAT3 signaling pathway. PloS One, 8, e55487.
18. Nauta, A. J., Kruisselbrink, A. B., Lurvink, E., Willemze, R., & Fibbe, W. E. (2006). Mesenchymal stem cells inhibit generation and function of both CD34+−derived and monocyte-derived dendritic cells. Journal of Immunology, 177, 2080–2087.
19. Ramasamy, R., Fazekasova, H., Lam, E. W., Soeiro, I., Lombardi, G., & Dazzi, F. (2007). Mesenchymal stem cells inhibit dendritic cell differentiation and function by preventing entry into the cell cycle. Transplantation, 83, 71–76.
20. Saeidi, M., Masoud, A., Shakiba, Y., et al. (2013). Immunomodulatory effects of human umbilical cord Wharton’s jelly-derived mesenchymal stem cells on differentiation, maturation and endocytosis of monocyte-derived dendritic cells. Iranian Journal of Allergy, Asthma, and Immunology, 12, 37–49.
21. Jiang, X. X., Zhang, Y., Liu, B., et al. (2005). Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood, 105, 4120–4126.
22. Kronsteiner, B., Peterbauer-Scherb, A., Grillari-Voglauer, R., et al. (2011). Human mesenchymal stem cells and renal tubular epithelial cells differentially influence monocyte-derived dendritic cell differentiation and maturation. Cellular Immunology, 267, 30–38.
23. Ivanova-Todorova, E., Bochev, I., Mourdjeva, M., et al. (2009). Adipose tissue-derived mesenchymal stem cells are more potent suppressors of dendritic cells differentiation compared to bone marrow-derived mesenchymal stem cells. Immunology Letters, 126, 37–42.
24. Romani, N., Gruner, S., Brang, D., et al. (1994). Proliferating dendritic cell progenitors in human blood. The Journal of Experimental Medicine, 180, 83–93.
25. Sallusto, F., & Lanzavecchia, A. (1994). Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. The Journal of Experimental Medicine, 179, 1109–1118.
26. Chapuis, F., Rosenzwajg, M., Yagello, M., Ekman, M., Biberfeld, P., & Gluckman, J. C. (1997). Differentiation of human dendritic cells from monocytes in vitro. European Journal of Immunology, 27, 431–441.
27. Banchereau, J., Briere, F., Caux, C., et al. (2000). Immunobiology of dendritic cells. Annual Review of Immunology, 18, 767–811.
28. Liu, Y. J., Kanzler, H., Soumelis, V., & Gilliet, M. (2001). Dendritic cell lineage, plasticity and cross-regulation. Nature Immunology, 2, 585–589.
29. Mellman, I., & Steinman, R. M. (2001). Dendritic cells: specialized and regulated antigen processing machines. Cell, 106, 255–258.
30. Banchereau, J., & Steinman, R. M. (1998). Dendritic cells and the control of immunity. Nature, 392, 245–252.
31. Lu, L., Woo, J., Rao, A. S., et al. (1994). Propagation of dendritic cell progenitors from normal mouse liver using granulocyte/macrophage colony-stimulating factor and their maturational development in the presence of type-1 collagen. The Journal of Experimental Medicine, 179, 1823–1834.
32. Lu, L., McCaslin, D., Starzl, T. E., & Thomson, A. W. (1995). Bone marrow-derived dendritic cell progenitors (NLDC 145+, MHC class II+, B7-1dim, B7-2-) induce alloantigen-specific hyporesponsiveness in murine T lymphocytes. Transplantation, 60, 1539–1545.
33. Fu, F., Li, Y., Qian, S., et al. (1996). Costimulatory molecule-deficient dendritic cell progenitors (MHC class II+, CD80dim, CD86-) prolong cardiac allograft survival in nonimmunosuppressed recipients. Transplantation, 62, 659–665.
34. Dhodapkar, M. V., Steinman, R. M., Krasovsky, J., Munz, C., & Bhardwaj, N. (2001). Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. The Journal of Experimental Medicine, 193, 233–238.
35. Jonuleit, H., Schmitt, E., Schuler, G., Knop, J., & Enk, A. H. (2000). Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. The Journal of Experimental Medicine, 192, 1213–1222.
36. Hackstein, H., Morelli, A. E., & Thomson, A. W. (2001). Designer dendritic cells for tolerance induction: guided not misguided missiles. Trends in Immunology, 22, 437–442.
37. Dubois, B., Bridon, J. M., Fayette, J., et al. (1999). Dendritic cells directly modulate B cell growth and differentiation. Journal of Leukocyte Biology, 66, 224–230.
38. Gerosa, F., Baldani-Guerra, B., Nisii, C., Marchesini, V., Carra, G., & Trinchieri, G. (2002). Reciprocal activating interaction between natural killer cells and dendritic cells. The Journal of Experimental Medicine, 195, 327–333.
39. Josien, R., Heslan, M., Brouard, S., Soulillou, J. P., & Cuturi, M. C. (1998). Critical requirement for graft passenger leukocytes in allograft tolerance induced by donor blood transfusion. Blood, 92, 4539–4544.
40. Waldmann, H. (1999). Transplantation tolerance-where do we stand? Nature Medicine, 5, 1245–1248.
41. Sallusto, F., & Lanzavecchia, A. (1999). Mobilizing dendritic cells for tolerance, priming, and chronic inflammation. The Journal of Experimental Medicine, 189, 611–614.
42. Abumaree, M. H., Chamley, L. W., Badri, M., & El-Muzaini, M. F. (2012). Trophoblast debris modulates the expression of immune proteins in macrophages: a key to maternal tolerance of the fetal allograft? Journal of Reproductive Immunology, 94, 131–141.
43. Duluc, D., Delneste, Y., Tan, F., et al. (2007). Tumor-associated leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-associated macrophage-like cells. Blood, 110, 4319–4330.
44. Cheng, P., Corzo, C. A., Luetteke, N., et al. (2008). Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. The Journal of Experimental Medicine, 205, 2235–2249.
45. Oosterhoff, D., Lougheed, S., van de Ven, R., et al. (2012). Tumor-mediated inhibition of human dendritic cell differentiation and function is consistently counteracted by combined p38 MAPK and STAT3 inhibition. Oncoimmunology, 1, 649–658.
46. Gabrilovich, D. (2004). Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nature Reviews Immunology, 4, 941–952.
47. Lankford, C. S., & Frucht, D. M. (2003). A unique role for IL-23 in promoting cellular immunity. Journal of Leukocyte Biology, 73, 49–56.
48. Anton, K., Banerjee, D., & Glod, J. (2012). Macrophage-associated mesenchymal stem cells assume an activated, migratory, pro-inflammatory phenotype with increased IL-6 and CXCL10 secretion. PloS One, 7, e35036.
49. Magatti, M., De Munari, S., Vertua, E., et al. (2009). Amniotic mesenchymal tissue cells inhibit dendritic cell differentiation of peripheral blood and amnion resident monocytes. Cell Transplantation, 18, 899–914.
50. Lenschow, D. J., Walunas, T. L., & Bluestone, J. A. (1996). CD28/B7 system of T cell costimulation. Annual Review of Immunology, 14, 233–258.
51. Quezada, S. A., Jarvinen, L. Z., Lind, E. F., & Noelle, R. J. (2004). CD40/CD154 interactions at the interface of tolerance and immunity. Annual Review of Immunology, 22, 307–328.
52. Zheng, Y., Manzotti, C. N., Liu, M., Burke, F., Mead, K. I., & Sansom, D. M. (2004). CD86 and CD80 differentially modulate the suppressive function of human regulatory T cells. Journal of Immunology, 172, 2778–2784.
53. Mahnke, K., Schmitt, E., Bonifaz, L., Enk, A. H., & Jonuleit, H. (2002). Immature, but not inactive: the tolerogenic function of immature dendritic cells. Immunology and Cell Biology, 80, 477–483.
54. Sharpe, A. H., & Freeman, G. J. (2002). The B7-CD28 superfamily. Nature Reviews Immunology, 2, 116–126.
55. van Kooten, C., & Banchereau, J. (2000). CD40-CD40 ligand. Journal of Leukocyte Biology, 67, 2–17.
56. Gudmundsdottir, H., & Turka, L. A. (1999). T cell costimulatory blockade: new therapies for transplant rejection. Journal of the American Society of Nephrology: JASN, 10, 1356–1365.
57. Wekerle, T., Kurtz, J., Bigenzahn, S., Takeuchi, Y., & Sykes, M. (2002). Mechanisms of transplant tolerance induction using costimulatory blockade. Current Opinion in Immunology, 14, 592–600.
58. Li, Y., Li, X. C., Zheng, X. X., Wells, A. D., Turka, L. A., & Strom, T. B. (1999). Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance. Nature Medicine, 5, 1298–1302.
59. Ou, D., Wang, X., Metzger, D. L., et al. (2006). Suppression of human T-cell responses to beta-cells by activation of B7-H4 pathway. Cell Transplantation, 15, 399–410.
60. Ueno, T., Yeung, M. Y., McGrath, M., et al. (2012). Intact B7-H3 signaling promotes allograft prolongation through preferential suppression of Th1 effector responses. European Journal of Immunology, 42, 2343–2353.
61. Yamaura, K., Watanabe, T., Boenisch, O., et al. (2010). In vivo function of immune inhibitory molecule B7-H4 in alloimmune responses. American Journal of Transplantation: Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 10, 2355–2362.
62. Wang, X., Hao, J., Metzger, D. L., et al. (2009). Local expression of B7-H4 by recombinant adenovirus transduction in mouse islets prolongs allograft survival. Transplantation, 87, 482–490.
63. Latchman, Y., Wood, C. R., Chernova, T., et al. (2001). PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nature Immunology, 2, 261–268.
64. Tseng, S. Y., Otsuji, M., Gorski, K., et al. (2001). B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells. The Journal of Experimental Medicine, 193, 839–846.
65. Carter, L., Fouser, L. A., Jussif, J., et al. (2002). PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2. European Journal of Immunology, 32, 634–643.
66. Freeman, G. J., Long, A. J., Iwai, Y., et al. (2000). Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. The Journal of Experimental Medicine, 192, 1027–1034.
67. Ozkaynak, E., Wang, L., Goodearl, A., et al. (2002). Programmed death-1 targeting can promote allograft survival. Journal of Immunology, 169, 6546–6553.
68. Munn, D. H., Sharma, M. D., Baban, B., et al. (2005). GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity, 22, 633–642.
69. Huang, L., Baban, B., Johnson, B. A., 3rd, & Mellor, A. L. (2010). Dendritic cells, indoleamine 2,3 dioxygenase and acquired immune privilege. International Reviews of Immunology, 29, 133–155.
70. Belladonna, M. L., Puccetti, P., Orabona, C., et al. (2007). Immunosuppression via tryptophan catabolism: the role of kynurenine pathway enzymes. Transplantation, 84, S17–S20.
71. Brenk, M., Scheler, M., Koch, S., et al. (2009). Tryptophan deprivation induces inhibitory receptors ILT3 and ILT4 on dendritic cells favoring the induction of human CD4+CD25+ Foxp3+ T regulatory cells. Journal of Immunology, 183, 145–154.
72. Grohmann, U., Orabona, C., Fallarino, F., et al. (2002). CTLA-4-Ig regulates tryptophan catabolism in vivo. Nature Immunology, 3, 1097–1101.
73. Munn, D. H., Zhou, M., Attwood, J. T., et al. (1998). Prevention of allogeneic fetal rejection by tryptophan catabolism. Science, 281, 1191–1193.
74. Van Parijs, L., Perez, V. L., Biuckians, A., Maki, R. G., London, C. A., & Abbas, A. K. (1997). Role of interleukin 12 and costimulators in T cell anergy in vivo. The Journal of Experimental Medicine, 186, 1119–1128.
75. Boussiotis, V. A., Tsai, E. Y., Yunis, E. J., et al. (2000). IL-10-producing T cells suppress immune responses in anergic tuberculosis patients. The Journal of Clinical Investigation, 105, 1317–1325.
76. Albert, M. L., Pearce, S. F., Francisco, L. M., et al. (1998). Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. The Journal of Experimental Medicine, 188, 1359–1368.
77. Eliopoulos, N., Francois, M., Boivin, M. N., Martineau, D., & Galipeau, J. (2008). Neo-organoid of marrow mesenchymal stromal cells secreting interleukin-12 for breast cancer therapy. Cancer Research, 68, 4810–4818.
78. Xue, Q., Luan, X. Y., Gu, Y. Z., et al. (2010). The negative co-signaling molecule b7-h4 is expressed by human bone marrow-derived mesenchymal stem cells and mediates its T-cell modulatory activity. Stem Cells and Development, 19, 27–38.
79. Djouad, F., Charbonnier, L. M., Bouffi, C., et al. (2007). Mesenchymal stem cells inhibit the differentiation of dendritic cells through an interleukin-6-dependent mechanism. Stem Cells, 25, 2025–2032.
80. Reyes-Moreno, C., Frenette, G., Boulanger, J., Lavergne, E., Govindan, M. V., & Koutsilieris, M. (1995). Mediation of glucocorticoid receptor function by transforming growth factor beta I expression in human PC-3 prostate cancer cells. The Prostate, 26, 260–269.
81. Miller, A. H., Pariante, C. M., & Pearce, B. D. (1999). Effects of cytokines on glucocorticoid receptor expression and function. Glucocorticoid resistance and relevance to depression. Advances in Experimental Medicine and Biology, 461, 107–116.
82. Chiesa, S., Morbelli, S., Morando, S., et al. (2011). Mesenchymal stem cells impair in vivo T-cell priming by dendritic cells. Proceedings of the National Academy of Sciences of the United States of America, 108, 17384–17389.